No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MYGN240816P27000
- 1.45
- -0.55-27.50%
15min DelayClose Jul 22 16:00 ET
1.45High1.45Low
1.45Open2.00Pre Close1 Volume20 Open Interest27.00Strike Price145.00Turnover54.55%IV7.93%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.45Extrinsic Value100Contract SizeAmericanOptions Type-0.3878Delta0.0968Gamma23.62Leverage Ratio-0.0290Theta-0.0073Rho-9.16Eff Leverage0.0279Vega
Intraday
- 5D
- Daily
News
Myriad Genetics (NASDAQ:MYGN) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only
What We Don't Know Can Hurt: New Cancer Risk Survey From Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Express News | Myriad Genetics Inc : TD Cowen Raises Target Price to $28 From $23
Express News | Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Comments
$Myriad Genetics(MYGN.US$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE
1
14
The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.
Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.
The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.
The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.
Read more
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
TrytosaveabitOP Jaguar8: Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 TrytosaveabitOP: What volume do you usually set like 1M?
TrytosaveabitOP Jaguar8: 300K in 3 minutes
Jaguar8 TrytosaveabitOP: Wow that is fast volume
View more comments...